Table 1.

CALGB Lung Cancer Studies (N = 11) From Which Patients Were Drawn

Disease, Stage, and Study	Treatment Arms	Enrollment Dates	No. of Patients Enrolled	No. of Patients Eligible	Eligible Patients With Education Data		No. of Deaths Among Eligible Patients With Education Data	Date of Last Follow-Up*
					No.	%
Total lung			2,350	2,210	1,577	71	1,491
NSCLC			1,616	1,505	1,177	78	1,127
Advanced
8931	Cisplatin, etoposide, placebo	August 1989-February 1991	291	266	227	85	225	June 2000
	Cisplatin, etoposide, hydrazine
9532	Vinorelbine, ifosfamide	September 1995-July 1996	100	93	81	87	74	October 2002
	Paclitaxel, ifosfamide
9730	Paclitaxel	December 1997-January 2001	584	561	505	90	494	September 2004
	Paclitaxel, carboplatin
9731	Paclitaxel	September 1997-April 1998	39	38	38	100	35	February 2002
Stage III
8831	Vinblastine, cisplatin → RT → cisplatin, vinblastine	August 1988-October 1989	91	85	73	86	67	October 2000
	Vinblastine, cisplatin → RT, carboplatin
9130	Vinblastine, cisplatin → RT	September 1991-November 1996	283	250	69	28†‡	64	October 2001
	Vinblastine, cisplatin → RT, carboplatin
9431	Cisplatin, gemcitabine → cisplatin, gemcitabine, RT	January 1996-June 1998	187	172	149	87	136	February 2004
	Cisplatin, paclitaxel → cisplatin, paclitaxel, RT
	Cisplatin, vinorelbine → cisplatin, vinorelbine, RT
9534	Paclitaxel, carboplatin → paclitaxel, carboplatin, RT	August 1996-January 1999	41	40	35	88	32	July 2003
SCLC			734	705	400	57	364
Limited
9235	Etoposide, cisplatin → RT	August 1993-January 1999	319	307	247	80	213	October 2005
	Etoposide, cisplatin → RT + carboplatin
Extensive
9033	Oral etoposide, IV cisplatin	February 1991-October 1993	319	306	74	24†‡	73	May 1997
	IV etoposide, IV cisplatin
9430	Cisplatin, topotecan, G-CSF	May 1995-June 1999	96	92	79	86	78	February 2002
	Cisplatin, paclitaxel 230 mg/m2, G-CSF
	Paclitaxel 230 mg/m2, topotecan, G-CSF
	Paclitaxel 175 mg/m2, topotecan, G-CSF

Abbreviations: CALGB, Cancer and Leukemia Group B; NSCLC, non–small-cell lung cancer; RT, radiotherapy; SCLC, small-cell lung cancer; IV, intravenous; G-CSF, granulocyte colony-stimulating factor.

^*The latest recorded date of death or date of last follow-up used to compute survival time among patients included in analyses.

^†When CALGB 9033 and 9130 were originally activated, the submission of a Background Information Form to the CALGB Statistical Center was not a requirement.

^‡Percent of eligible patients.